Navigating State Telehealth Prescribing Requirements for Semaglutide and Tirzepatide

The rapid growth of telehealth has revolutionized access to healthcare, including for weight management. Medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which are GLP-1 receptor agonists, have emerged as highly effective tools for chronic weight management and diabetes. However, their prescribing via telehealth platforms is subject to a complex and evolving patchwork of state-specific regulations, primarily governed by state medical boards and legislative bodies.

The Core Regulatory Challenge: Establishing a Valid Practitioner-Patient Relationship

At the heart of telehealth prescribing regulations is the requirement to establish a valid practitioner-patient relationship. This fundamental principle ensures that a healthcare provider has sufficient information and interaction with a patient to render a diagnosis and prescribe treatment safely and effectively. While federal agencies like the DEA have historically maintained an in-person exam requirement for controlled substances (though this has been subject to waivers and proposed changes), state medical boards define what constitutes a valid relationship for all prescribing, including non-controlled substances like semaglutide and tirzepatide.

Many states have adopted the principle that the standard of care for telehealth encounters should be equivalent to that of in-person care. This often translates to requirements for:

• A comprehensive medical history.
• A physical examination, which may or may not be required to be in-person for the initial visit, depending on the state and the nature of the condition.
• Review of relevant diagnostic tests.
• Development of a treatment plan.
• Maintenance of appropriate medical records.

State-Specific Nuances and Examples

While a comprehensive state-by-state analysis is beyond a single article, it's crucial to understand the types of variations practitioners will encounter.

States Requiring In-Person Exam for Initial Prescribing (or specific conditions)

Some states maintain stricter requirements, especially for new patient relationships or for conditions deemed complex or high-risk. For example:

• Texas: The Texas Medical Board's rules on telemedicine generally allow for the establishment of a practitioner-patient relationship via synchronous audio-visual technology. However, the rules emphasize that the physician must use appropriate diagnostic and treatment modalities and maintain a standard of care equivalent to in-person care. For certain conditions or medications, an in-person component might be implicitly or explicitly required to meet this standard. (Refer to Texas Occupations Code § 111.001 et seq. and Texas Administrative Code Title 22, Part 9, Chapter 174).
• North Carolina: The North Carolina Medical Board's position statement on telemedicine states that a physician-patient relationship can be established via real-time audio-visual communication. However, it also stresses that the physician must ensure the appropriateness of the encounter and may need to refer the patient for an in-person exam if necessary to meet the standard of care. (Refer to N.C. Gen. Stat. § 90-12.1 and NC Medical Board Position Statement on Telemedicine).

States with More Flexible Telehealth Prescribing Rules

Other states have more explicitly embraced telehealth for establishing initial relationships, provided the technology allows for a thorough evaluation.

• Florida: The Florida Board of Medicine generally permits the establishment of a patient-physician relationship via telehealth. However, there are specific restrictions for prescribing controlled substances. For non-controlled substances like semaglutide, the focus remains on the physician's responsibility to conduct an appropriate medical evaluation. (Refer to Florida Statutes § 456.47 and Florida Administrative Code Rule 64B8-9.014).
• California: The Medical Board of California's guidelines emphasize that the standard of care applies regardless of the modality. A physician-patient relationship can be established via telehealth if the physician performs an appropriate examination and evaluation consistent with the standard of care. (Refer to California Business and Professions Code § 2290.5 and Medical Board of California Telehealth Guidelines).

Specific Considerations for Weight Management Medications

Prescribing semaglutide and tirzepatide for weight management carries additional considerations:

1. Off-Label Use vs. Approved Indications: While Wegovy and Zepbound are FDA-approved for chronic weight management, Ozempic and Mounjaro are approved for type 2 diabetes. Prescribing Ozempic or Mounjaro for weight management in non-diabetic patients constitutes off-label use. While legal, it requires robust documentation of medical necessity, informed consent, and adherence to the standard of care, especially when prescribed via telehealth.
2. Compounding Pharmacies: The use of compounded versions of semaglutide or tirzepatide has become prevalent due to shortages and cost. However, state medical boards, in conjunction with state boards of pharmacy, are scrutinizing these practices. Practitioners must ensure that compounded medications are used appropriately, meet state compounding regulations, and are not simply used to bypass FDA approval or supply chain issues without proper justification. The FDA has issued warnings regarding compounded GLP-1s, and states often follow suit with their own guidance. (Refer to FDA.gov statements on compounded GLP-1s).
3. Ancillary Services and Supervision: For clinics like medspas offering these treatments, the role of supervising physicians and the delegation of tasks to advanced practice providers (NPs, PAs) must strictly adhere to state scope of practice laws and supervision requirements. This is particularly critical in a telehealth context where direct, in-person supervision may be less frequent.

Documentation is Paramount

Regardless of the state, meticulous documentation is the practitioner's strongest defense in a regulatory inquiry. For telehealth prescribing of weight management medications, records should clearly demonstrate:

• Patient Identity Verification: How the patient's identity was confirmed.
• Informed Consent: Discussion of risks, benefits, alternatives, and the off-label status if applicable.
• Comprehensive Evaluation: Detailed history, review of systems, relevant physical exam findings (even if remote), and diagnostic test results (e.g., labs for kidney function, thyroid, A1C).
• Medical Necessity: Clear justification for the prescription based on clinical guidelines (e.g., BMI criteria for weight management).
• Monitoring Plan: How the patient will be monitored for efficacy and adverse effects.
• Referral Plan: When and how an in-person evaluation or specialty referral would be made.

Conclusion

The regulatory environment for telehealth prescribing of semaglutide, tirzepatide, and other weight management medications is dynamic and state-specific. Healthcare providers and businesses operating in this space must proactively understand and comply with the specific rules of every state in which they practice. Failure to do so can result in severe consequences, including license sanctions, fines, and civil or criminal penalties. Staying informed through direct consultation of state medical board websites and engaging with legal counsel specializing in healthcare regulatory compliance is essential for mitigating risk and ensuring patient safety.

---

References

• Texas Medical Board (TMB) - Telemedicine Rules: https://www.tmb.state.tx.us/page/board-rules (Specifically, Texas Administrative Code Title 22, Part 9, Chapter 174, and Occupations Code § 111.001 et seq.)
• North Carolina Medical Board (NCMB) - Position Statements: https://www.ncmedboard.org/resources-page/position-statements (Refer to the Telemedicine Position Statement and N.C. Gen. Stat. § 90-12.1)
• Florida Board of Medicine - Telehealth: https://flboardofmedicine.gov/ (Refer to Florida Statutes § 456.47 and Florida Administrative Code Rule 64B8-9.014)
• Medical Board of California (MBC) - Telehealth: https://www.mbc.ca.gov/ (Refer to California Business and Professions Code § 2290.5 and Telehealth Guidelines)
• U.S. Food and Drug Administration (FDA) - Information on Compounded GLP-1s: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-unapproved-versions-semaglutide-drugs-ozempic-and-wegovy